An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Inclusion Criteria: * Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by BMI ≥30 and ≤60 kg/m2 * Greater than 6 months post-treatment, including chemotherapy, surgery or radiation with resulting injury to the hypothalamus and/or the pituitary * Stable body weight for at least 3 months * Type 2 diabetes mellitus is allowed Exclusion Criteria: * Males taking gonadotropin replacement therapy (LH/FSH) * Subjects who are planning any fertility treatment within 6 months of study participation * Use of weight loss agents, including herbal medications, in the past 3 months * Current or anticipated chronic use of narcotics or opiates * History of severe psychiatric disorders * Type 1 diabetes mellitus * Metabolic disorders or genetic disorders linked to obesity * History of any bariatric surgery * Participation in any clinical study with an investigational drug or device within the 3 months prior to enrollment in this study * Blood loss or donation \>500 mL within the past 3 months * Females who are pregnant, nursing, intend to become pregnant during the study or any males who plan to father/conceive a child within 6 months after completion of study participation